69 results
6-K
EX-99.1
IPHA
Innate Pharma
4 Jun 24
Innate Pharma presents positive results from TELLOMAK Phase 2 study with lacutamab in mycosis fungoides
6:03am
drug status in the European Union and in the United States for the treatment of CTCL.
About TELLOMAK
TELLOMAK (NCT03902184) is a global, open-label
6-K
EX-1.1
efhtack3
6 Feb 24
Current report (foreign)
5:05pm
424B5
kn03o zdxp
6 Feb 24
Prospectus supplement for primary offering
5:00pm
6-K
EX-99.1
8mz615es6l2
4 Jan 24
FDA lifts partial clinical hold on lacutamab clinical programFatal case related to disease progression and unrelated to the treatment
6:01am
F-3
23ninfjob 4r9
20 Dec 23
Shelf registration (foreign)
4:45pm
F-3
EX-3.1
jbuhhmpl 92e8mb
20 Dec 23
Shelf registration (foreign)
4:45pm
6-K
EX-99.1
hr8l2oktj0
11 Dec 23
Innate Pharma S.a. 6-K
6:01am
6-K
EX-99.1
dupbdvbu0u3j0z x3p
27 Nov 23
Innate Pharma S.a. 6-K
6:00am
6-K
EX-99.1
7ou248vxqic54o7wuj
5 Oct 23
Innate Pharma S.a. 6-K
6:00am
6-K
EX-99.1
hgbdu
22 Sep 23
Innate Pharma S.a. 6-K
6:00am
6-K
EX-99.2
vv6 j43lo265
14 Sep 23
Innate Pharma Reports First Half 2023 Financial Results and Business Update
6:27am
6-K
EX-99.1
c9a87k8tsmw tysb78k6
14 Sep 23
Innate Pharma Reports First Half 2023 Financial Results and Business Update
6:27am
6-K
EX-99.1
u9sim oy4g81w8zxc
14 Sep 23
Innate Pharma S.a. 6-K
6:00am
6-K
EX-99.1
lwdny y55a0hkkhm6c21
16 Jun 23
Innate Pharma S.a. 6-K
6:00am
6-K
EX-99.1
yj97ruil
12 Jun 23
Innate Pharma S.a. 6-K
6:01am
6-K
EX-1.1
b9rqf ref2c1wg2m
26 Apr 23
Current report (foreign)
4:02pm